Osteopore マネジメント

マネジメント基準チェック /24

Osteoporeの CEO はYujing Limで、 Sep2019年に任命され、の在任期間は 5.17年です。の年間総報酬はA$ 202.25Kで、 91.8%給与と8.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.14%を直接所有しており、その価値はA$ 6.50K 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と1.8年です。

主要情報

Yujing Lim

最高経営責任者

AU$202.2k

報酬総額

CEO給与比率	91.8%
CEO在任期間	5.2yrs
CEOの所有権	0.1%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	1.8yrs

経営陣の近況

Recent updates

We Think Osteopore (ASX:OSX) Needs To Drive Business Growth Carefully

Aug 24

How Many Osteopore Limited (ASX:OSX) Shares Have Insiders Sold, In The Last Year?

Dec 29

CEO報酬分析

Osteopore の収益と比較して、Yujing Lim の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-AU$4m
Mar 31 2024	n/a	n/a	-AU$4m
Dec 31 2023	AU$202k	AU$186k	-AU$5m
Sep 30 2023	n/a	n/a	-AU$5m
Jun 30 2023	n/a	n/a	-AU$5m
Mar 31 2023	n/a	n/a	-AU$5m
Dec 31 2022	AU$164k	AU$149k	-AU$4m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	n/a	n/a	-AU$4m
Mar 31 2022	n/a	n/a	-AU$4m
Dec 31 2021	AU$132k	AU$118k	-AU$4m
Sep 30 2021	n/a	n/a	-AU$3m
Jun 30 2021	n/a	n/a	-AU$3m
Mar 31 2021	n/a	n/a	-AU$2m
Dec 31 2020	AU$124k	AU$109k	-AU$2m
Sep 30 2020	n/a	n/a	-AU$2m
Jun 30 2020	n/a	n/a	-AU$2m
Mar 31 2020	n/a	n/a	-AU$2m
Dec 31 2019	AU$39k	AU$34k	-AU$2m

報酬と市場: Yujingの総報酬 ($USD 134.15K ) は、 Australian市場 ($USD 304.34K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Yujingの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Yujing Lim

5.2yrs

在職期間

AU$202,246

報酬

Dr. Yujing Lim, Ph. D. (Singapore), is Chief Executive Officer of Osteopore Limited from July 18, 2023 and serves as its Chief Technology Officer since May 01, 2022 as well as its Executive Director since...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kei Wei Leong	Executive Chairman	3.3yrs	AU$214.90k	0.12% A$ 5.5k
Yujing Lim	CEO, CTO & Executive Director	5.2yrs	AU$202.25k	0.14% A$ 6.5k
Shu Voon	Financial Controller	1.8yrs	データなし	データなし
Khoon Seng Goh	Global Marketing Director	1.3yrs	AU$212.90k	データなし

2.4yrs

平均在職期間

経験豊富な経営陣: OSXの経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Kei Wei Leong	Executive Chairman	3.3yrs	AU$214.90k	0.12% A$ 5.5k
Yujing Lim	CEO, CTO & Executive Director	less than a year	AU$202.25k	0.14% A$ 6.5k
David Yeow	Member of Advisory Board	1.8yrs	データなし	データなし
Swee Hin Teoh	Non Executive Director	5.4yrs	AU$46.36k	0.51% A$ 23.8k
Daniel Ow	Independent Non-Executive Director	3.1yrs	AU$46.36k	データなし
Greg Rudd	Member of Advisory Board	1.8yrs	データなし	データなし
Michael Wagels	Member of Advisory Board	1.8yrs	データなし	データなし
Joy Song	Member of Advisory Board	1.8yrs	データなし	データなし
Samintharaj Kumar	Member of Advisory Board	1.8yrs	データなし	データなし
James Tan	Member of Advisory Board	1.8yrs	データなし	データなし
GK Ananda	Member of Advisory Board	1.8yrs	データなし	データなし
Michael Keenan	Director	1.3yrs	AU$18.24k	データなし

1.8yrs

平均在職期間

経験豊富なボード: OSXの取締役会は経験豊富ではない ( 1.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Osteopore マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Osteopore Limited Appoints Yujing Lim as Executive Director

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 30, 2024

Osteopore Limited Announces Resignation of Deborah Ho as Joint Company Secretary

Osteopore Limited Announces Appointment of Kellie Davis as Joint Company Secretary, Effective 26 January 2023

Less than half of directors are independent

Recent updates

Osteopore Limited Appoints Yujing Lim as Executive Director

New major risk - Shareholder dilution

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 30, 2024

Osteopore Limited has filed a Follow-on Equity Offering in the amount of AUD 2.99532 million.

Full year 2023 earnings released: AU$0.031 loss per share (vs AU$0.51 loss in FY 2022)

New minor risk - Share price stability

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Osteopore Limited Announces Resignation of Deborah Ho as Joint Company Secretary

First half 2023 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in 1H 2022)

Full year 2022 earnings released: AU$0.034 loss per share (vs AU$0.031 loss in FY 2021)

Osteopore Limited Enters Orthopaedic Market in Great Britain

Osteopore Limited Announces Appointment of Kellie Davis as Joint Company Secretary, Effective 26 January 2023

Osteopore Limited (ASX:OSX) agreed to acquire Businesses Of Lomic Korea, 3D Aesthetic Solutions, 3D Healthcare Solutions And 3D Aesthetic Medical Lim Jae Hoon from Lim Jae Hoon for AUD2.05 million.

Less than half of directors are independent

First half 2022 earnings released: AU$0.017 loss per share (vs AU$0.012 loss in 1H 2021)

Insider recently bought AU$1.9m worth of stock

We Think Osteopore (ASX:OSX) Needs To Drive Business Growth Carefully

Osteopore Limited Announces Appointment of Dr. Lim Jing as Chief Operating Officer

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Osteopore Limited Announces Resignation of Vlado Bosanac as Non-Executive Director

High number of new and inexperienced directors

High number of new and inexperienced directors

First half 2021 earnings released: AU$0.012 loss per share (vs AU$0.007 loss in 1H 2020)

Non Executive Chairman Brett Sandercock has left the company

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

New 90-day low: AU$0.47

Osteopore Limited Announces A Cooperation Agreement with Terumo Blood and Cell Technologies

Osteopore International Collaborates with Maastricht University Medical Centre to Develop Implant Solution That Prevents Leg Amputations

New 90-day low: AU$0.50

How Many Osteopore Limited (ASX:OSX) Shares Have Insiders Sold, In The Last Year?

New 90-day low: AU$0.51

New 90-day high: AU$0.61

Osteopore Limited Signs Distribution Agreement with MTG Medizintechnik Göhl

Osteopore Limited Announce the Appointment of Carl Runde as Chief Financial Officer

First half earnings released

Osteopore Limited has completed a Follow-on Equity Offering in the amount of AUD 8.5 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /24